Clinical Trials Logo

Methicillin Resistance clinical trials

View clinical trials related to Methicillin Resistance.

Filter by:
  • None
  • Page 1

NCT ID: NCT00846105 Completed - Clinical trials for Staphylococcus Aureus

Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)

Start date: February 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of a novel PCR-based laboratory test for rapid detection of MRSA carriers to prevent transmission of MRSA in the Belgian acute care hospital setting.

NCT ID: NCT00541632 Terminated - Clinical trials for Methicillin Resistance

BacLite Rapid MRSA Clinical Performance

Start date: October 2007
Phase: N/A
Study type: Observational

The purpose of this study is to compare the performance of the 3M(TM) BacLite (TM) Rapid MRSA test system to traditional culture methods in detecting the presence of Methicillin Resistant Staphylococcus aureus (MRSA) directly from nasal samples.

NCT ID: NCT00254527 Completed - Clinical trials for Staphylococcus Aureus

Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.

Start date: January 2005
Phase: N/A
Study type: Observational

The intent of this study is to: 1. Define the prevalence of MRSA carriage in the pediatric population in Kansas City. 2. Systematically define patient risk factors for MRSA carriage and infection. 3. Characterize the unique genetic characteristics of MRSA strains, both community acquired (CA) and healthcare associated (HCA) that are present in the different pediatric populations.

NCT ID: NCT00079976 Completed - Clinical trials for Gram-Positive Bacterial Infections

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

Start date: October 2003
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.